RARE Daily

Nanomedicines Developer ViaNautis Bio Raises $25 Million

November 13, 2023

Rare Daily Staff

British genetic medicines biotech ViaNautis Bio has raised $25 million (£20 million) in a series A financing to advance its proprietary drug delivery platform called polyNaut.

4BIO Capital, BGF and UCB Ventures co-led the financing with the additional participation of the Cystic Fibrosis Foundation, Eli Lilly, and existing investors including Origin Capital, Meltwind and O2H. The proceeds from the round will fuel the rapid development of products using the polyNaut platform, expand the scientific and management teams and establish industry-leading laboratory facilities.

ViaNautis says its polyNaut platform applies advanced polymer materials and in silico screening to precisely guide genetic molecules such as pDNA, mRNA, siRNA and ASOs to their intended targets. Unlike conventional drug delivery methods, polyNaut tackles the challenge of transporting genetic materials across biological barriers, advancing medicines for conditions with pressing unmet clinical needs, such as cystic fibrosis – a multisystemic disease affecting the lungs, pancreas, and other organs—and central nervous system diseases. The company’s pipeline includes VNS002, supported by the Cystic Fibrosis Foundation, focusing on identifying optimal formulation candidates for targeted delivery to the conducting airways in the lungs.

ViaNautis, formerly known as SomaServe, was spun out of UCL in 2018 by co-founders Francesca Crawford, Denis Cecchin, and Professor Giuseppe Battaglia, inventor of polyNaut and honorary professor at UCL. Battaglia is also an ICREA professor and head of the Molecular Bionics Group at the Institute for Bioengineering of Catalonia, part of the Barcelona Institute for Science and Technology (IBEC).

“This successful fundraise empowers us to expedite the deployment of our proprietary polyNaut technology, which offers unparalleled access to the brain and other tissues, presenting significant opportunities to address both CNS and lung diseases,” said Francesca Crawford, CEO of ViaNautis.

Photo: Francesca Crawford, CEO of ViaNautis

Stay Connected

Sign up for updates straight to your inbox.

FacebookTwitterInstagramYoutube